您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览12

In patients with chronic kidney disease (CKD), hypertension (HP) is associated with the development of left ventricular (LV) diastolic dysfunction. However, the impact of antihypertensive treatment on LV diastolic function has not been well studied in CKD patients. Recently, two-dimensional speckle-tracking echocardiography (2DSTE) has emerged as a sensitive and quantitative assessment of LV diastolic function. The present study used 2DSTE to investigate the effects of antihypertensive treatment on LV diastolic function in patients with CKD and untreated HP. The study comprised 134 patients with CKD and untreated HP. The patients received blood pressure (BP)-lowering therapy for six months. The patients were clinically and echocardiographically evaluated at baseline and after 6 months of therapy. It was found that the mean systolic BP (SBP) and diastolic BP (DBP) at baseline were 154.0±7.0 and 92.6±10.2 mmHg, respectively, decreasing to 121.2±7.3 and 74.6±10.4 mmHg, respectively (P<0.05 for both) after the 6-month treatment period. Moreover, the mean peak LV strain rate during the isovolumetric relaxation period (SRIVR) and early diastole (SRE) improved following treatment (from 0.23±0.10 to 0.42±0.10 sec-1 and from 0.58±0.25 to 1.07±0.24 sec-1, respectively; P<0.05 for both). Notably, the patients with CKD stage ≥3 were more likely to demonstrate an improvement in diastolic speckle-tracking parameters than those with CKD stage 1 or 2. For the entire population, the change (Δ) in B-type natriuretic peptide (BNP) level correlated with changes in echocardiographic parameters between baseline and follow-up, among which ΔSRIVR presented the highest correlation coefficient (r=-0.73, P<0.01). On multivariate analysis, the independent predictors of ΔSRIVR were found to include baseline CKD stage, SBP and SRIVR. This study demonstrated that LV diastolic function was improved in CKD patients following antihypertensive treatment, particularly in patients with CKD stage ≥3, higher baseline SBP and worse LV diastolic function. These results highlight the importance of BP reduction in the treatment of CKD.

作者:Ku-Lin, Li;Ru-Xing, Wang;Min, Dai;Juan, Lu;Jing, Xue;Xiang-Jun, Yang

来源:Experimental and therapeutic medicine 2015 年 9卷 5期

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:12
作者:
Ku-Lin, Li;Ru-Xing, Wang;Min, Dai;Juan, Lu;Jing, Xue;Xiang-Jun, Yang
来源:
Experimental and therapeutic medicine 2015 年 9卷 5期
标签:
antihypertensive therapy chronic kidney disease diastolic dysfunction-speckle tracking echocardiography
In patients with chronic kidney disease (CKD), hypertension (HP) is associated with the development of left ventricular (LV) diastolic dysfunction. However, the impact of antihypertensive treatment on LV diastolic function has not been well studied in CKD patients. Recently, two-dimensional speckle-tracking echocardiography (2DSTE) has emerged as a sensitive and quantitative assessment of LV diastolic function. The present study used 2DSTE to investigate the effects of antihypertensive treatment on LV diastolic function in patients with CKD and untreated HP. The study comprised 134 patients with CKD and untreated HP. The patients received blood pressure (BP)-lowering therapy for six months. The patients were clinically and echocardiographically evaluated at baseline and after 6 months of therapy. It was found that the mean systolic BP (SBP) and diastolic BP (DBP) at baseline were 154.0±7.0 and 92.6±10.2 mmHg, respectively, decreasing to 121.2±7.3 and 74.6±10.4 mmHg, respectively (P<0.05 for both) after the 6-month treatment period. Moreover, the mean peak LV strain rate during the isovolumetric relaxation period (SRIVR) and early diastole (SRE) improved following treatment (from 0.23±0.10 to 0.42±0.10 sec-1 and from 0.58±0.25 to 1.07±0.24 sec-1, respectively; P<0.05 for both). Notably, the patients with CKD stage ≥3 were more likely to demonstrate an improvement in diastolic speckle-tracking parameters than those with CKD stage 1 or 2. For the entire population, the change (Δ) in B-type natriuretic peptide (BNP) level correlated with changes in echocardiographic parameters between baseline and follow-up, among which ΔSRIVR presented the highest correlation coefficient (r=-0.73, P<0.01). On multivariate analysis, the independent predictors of ΔSRIVR were found to include baseline CKD stage, SBP and SRIVR. This study demonstrated that LV diastolic function was improved in CKD patients following antihypertensive treatment, particularly in patients with CKD stage ≥3, higher baseline SBP and worse LV diastolic function. These results highlight the importance of BP reduction in the treatment of CKD.